Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents

被引:57
作者
Singh, U [1 ]
Tabibian, J [1 ]
Venugopal, SK [1 ]
Devaraj, S [1 ]
Jialal, I [1 ]
机构
[1] Univ Calif Davis, Med Ctr, Dept Pathol & Lab Med, Lab Atherosclerosis & Metab Res, Sacramento, CA 95817 USA
关键词
D O I
10.1373/clinchem.2005.056093
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Monocytes- and macrophages are critical in atherosclerosis and on stimulation secrete proinflammatory, proatherogenic cytokines such as tumor necrosi s factor (TNF)-alpha and interleukin (W-113, which have been shown to be present in atherosclerotic lesions. The aim of this study was to develop a rapid in vitro screening assay to test the antiinflammatory effects of different compounds. Methods and Results: THP-1 cells (human monocytic cell line) were stimulated with different concentrations of lipopolysaccharide (LPS; 0 to 1000 mu g/L) and for different times (4, 12, and 24 h), and the secretion of proinflammatory cytokines (IL-1, IL-6, and TNF-alpha) was assessed. TNF-alpha secretion was maximum at the lowest LPS concentration (100 fxg/L) and at shortest duration of incubation (4 h). Maximum secretion of IL-1/3 and IL-6 was achieved at 24 h with higher doses of LPS. Treatment of THP-1 with various test compounds such as dietary supplements (alpha-tocopherol, N-acetylcysteine, catechin and epigallocatechin gallate) as well as pharmacologic agents (statins, peroxisome proliferator-activated receptor-y agonists, and an angiotensin H receptor blocker) significantly inhibited LPS-stimulated TNF-alpha release. Conclusions: The release of TNF-alpha after stimulation of THP-1 cells with LPS is a valid model system to test novel compounds for potential antfinflammatory effects. (c) 2005 American Association for Clinical Chemistry
引用
收藏
页码:2252 / 2256
页数:5
相关论文
共 34 条
[1]   Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients [J].
Ascer, E ;
Bertolami, MC ;
Venturinelli, ML ;
Buccheri, V ;
Souza, J ;
Nicolau, JC ;
Ramires, JAF ;
Serrano, CV .
ATHEROSCLEROSIS, 2004, 177 (01) :161-166
[2]  
BANKA CL, 1991, J LIPID RES, V32, P35
[3]   PPARs in atherosclerosis: the clot thickens [J].
Castrillo, A ;
Tontonoz, P .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (11) :1538-1540
[4]   Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications -: The effect of α-tocopherol supplementation [J].
Devaraj, S ;
Jialal, I .
CIRCULATION, 2000, 102 (02) :191-196
[5]   Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and Type 2 diabetic patients [J].
Devaraj, S ;
Jialal, I .
FREE RADICAL BIOLOGY AND MEDICINE, 2000, 29 (08) :790-792
[6]   Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase C-α and -β [J].
Devaraj, S ;
Venugopal, SK ;
Singh, U ;
Jialal, I .
DIABETES, 2005, 54 (01) :85-91
[7]   Modulation of monocyte-macrophage function with α-tocopherol:: Implications for atherosclerosis [J].
Devaraj, S ;
Harris, A ;
Jialal, I .
NUTRITION REVIEWS, 2002, 60 (01) :8-14
[8]   The effects of alpha tocopherol supplementation on monocyte function - Decreased lipid oxidation, interleukin 1 beta secretion, and monocyte adhesion to endothelium [J].
Devaraj, S ;
Li, D ;
Jialal, I .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (03) :756-763
[9]   Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus [J].
Haffner, SM ;
Greenberg, AS ;
Weston, WM ;
Chen, HZ ;
Williams, K ;
Freed, MI .
CIRCULATION, 2002, 106 (06) :679-684
[10]   Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-κB [J].
Håversen, L ;
Ohlsson, BG ;
Hahn-Zoric, M ;
Hanson, LÅ ;
Mattsby-Baltzer, I .
CELLULAR IMMUNOLOGY, 2002, 220 (02) :83-95